Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.

摘要: 2027 Background: The determinants of long-term survival in glioblastoma have remained largely obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common WHO grade 2/3 gliomas, but rare primary glioblastomas, and associated with longer survival. Methods: We compared clinical molecular characteristics 69 patients centrally confirmed > 36 months (LTS-36), including 33 surviving 60 (LTS-60), 259 < months. MGMT promoter methylation, 1p/19q codeletions, EGFR amplification, TP53 IDH1/2mutations were determined by standard techniques. Results: rate IDH1/2 LTS-36 was 34% (23/67 patients) as opposed to 4.3% controls (11/257 patients). Long-term survivors -mutant glioblastomas younger, had almost no amplifications, exhibited more often codeletions than LTS wild-type glioblastomas. Among patients,...